This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

53/100

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Lewy body dementia

Topic: Brain proteins, microglia and lab models

Plain-language summary

Of 293 participants screened, 130 were randomized, and 109 (83.8%) completed the study. Baseline characteristics were similar between groups. Discontinuation rates for adverse events were 4.5% for zervimesine 100 mg, 16.3% for zervimesine 300 mg, and 4.8% for placebo. This study demonstrated that zervimesine was safe and well tolerated. The favorable efficacy profile from exploratory outcomes provides a rationale for testing zervimesine in larger studies. This study was registered at ClinicalTrials.gov: NCT05225415. HIGHLIGHTS: This study evaluated the safety and efficacy of zervimesine in Lewy body dementia. The incidence of adverse events was comparable to zervimesine 100 mg and placebo. Favorable, consistent trends were observed with zervimesine for exploratory endpoints.

What this study adds

Evidence grade: High

The record lists 293 participants. In this phase 2 trial, 130 participants with mild-to-moderate dementia with Lewy bodies were randomized, and zervimesine was found to be safe and well tolerated, with favorable trends on exploratory endpoints. Reported effect size: 83.8%; 4.5%; 16.3%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Galvin, J. E., Tolea, M. I., Scharre, D. W., Hamby, M. E., Iaci, J. F., Grundman, M., et al. (2025). Phase 2 study of zervimesine (CT1812) in participants with mild‐to‐moderate dementia with Lewy bodies (DLB). Alzheimer s & Dementia. https://doi.org/10.1002/alz.71004

Vancouver

Galvin JE, Tolea MI, Scharre DW, Hamby ME, Iaci JF, Grundman M, et al. Phase 2 study of zervimesine (CT1812) in participants with mild‐to‐moderate dementia with Lewy bodies (DLB). Alzheimer s & Dementia. 2025. doi:10.1002/alz.71004. PMID: 41416579.

BibTeX

@article{galvin2025-41416579,
  author  = {Galvin, James E. and Tolea, Magdalena I. and Scharre, Douglas W. and Hamby, Mary E. and Iaci, Jennifer F. and Grundman, Michael and Caggiano, Anthony O.},
  title   = {{Phase 2 study of zervimesine (CT1812) in participants with mild‐to‐moderate dementia with Lewy bodies (DLB)}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.71004},
  pmid    = {41416579},
  url     = {https://doi.org/10.1002/alz.71004}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record lists 293 participants. Ask whether that is enough for the question, and who they were.
Effect: the record reports “83.8%; 4.5%; 16.3%”. A statistically significant result can still be small in daily life.

What the evidence grade means here

This page is graded high. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. High means the abstract mentions a randomized design, a meta-analysis or a systematic review. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Of 293 participants screened, 130 were randomized, and 109 (83.8%) completed the study.
Baseline characteristics were similar between groups.
Discontinuation rates for adverse events were 4.5% for zervimesine 100 mg, 16.3% for zervimesine 300 mg, and 4.8% for placebo.
This study demonstrated that zervimesine was safe and well tolerated.
The favorable efficacy profile from exploratory outcomes provides a rationale for testing zervimesine in larger studies.

Why it matters

In this phase 2 trial, 130 participants with mild-to-moderate dementia with Lewy bodies were randomized, and zervimesine was found to be safe and well tolerated, with favorable trends on exploratory endpoints. The authors state these results provide a rationale for testing zervimesine in larger studies, so efficacy for treating the disease is not yet established.

Study details

Participants293
Effect size83.8%; 4.5%; 16.3%
Evidence strengthHigh

How this study scored 53/100

Published in a peer-reviewed journal. Scored zero for study design because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 51 of the 96 points we could judge it on, which is 53 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	293 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	1 / 2	Randomized (as stated in the record)
Times cited	2 / 7	Cited 6 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.0 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 3.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	2 / 3	University of California San Diego: institution h-index 1,852 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41416579)
Free to read	2 / 2	Free to read
Points	51 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 96 points we could judge it on is 53 out of 100.
Total	53 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Lewy body dementia from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →